Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3294083 | Gastroenterology | 2013 | 11 Pages |
Abstract
Although mesalamine 4.8 g/day was not statistically different from placebo for induction of remission in patients with mildly to moderately active UC, based on an intent-to-treat analysis, the totality of the data supports a benefit of treatment. Central review of endoscopic images is critical to the conduct of induction studies in UC; ClinicalTrials.gov Number, NCT01059344.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Brian G. Feagan, William J. Sandborn, Geert D'Haens, Suresh Pola, John W.D. McDonald, Paul Rutgeerts, Pia Munkholm, Ulrich Mittmann, Debra King, Cindy J. Wong, Guangyong Zou, Allan Donner, Lisa M. Shackelton, Denise Gilgen, Sigrid Nelson,